Korea-based clinical biotechnology company D&D Pharmatech has raised a USD137 million Series B funding round led by US-based investment firm Octave Life Sciences. Korea-focused venture investors Smilegate Investment, InterVest, Magna Investment, and LB Investment also participated in the round, along with individual investors from the US and Korea. D&D Pharmatech focuses on the development and commercialization of biotechnology medicines through its project-specific subsidiaries, including Neuraly, Precision Molecular, and Theraly Fibrosis. The new capital will be utilized by D&D’s subsidiaries for clinical and preclinical drug research and development.